Deals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
Abogen BiosciencesmRNA

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Co., Ltd. ("Abogen"), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance…

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
CancerFinance

Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization

J&J MedTech Secures Exclusive Distribution Deal with Responsive Arthroscopy
BiotechJ&J

J&J MedTech Secures Exclusive Distribution Deal with Responsive Arthroscopy

Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China
Baheal PharmaceuticalBiostar Technologies

Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China

PegBio Files for IPO on Hong Kong Stock Exchange
FinanceIPO

PegBio Files for IPO on Hong Kong Stock Exchange

Show More